This is a preview of subscription content, log in via an institution to check access.
References
Ricciuti B, et al. Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. 19th World Conference on Lung Cancer : abstr. MA10.06, 23 Sep 2018.
Tarruella MM, et al. Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer. 19th World Conference on Lung Cancer : abstr. P1.01-63, 23 Sep 2018.
Virik K, et al. Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience. 19th World Conference on Lung Cancer : abstr. P3.01-04, 23 Sep 2018.
Sung M, et al. Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. 19th World Conference on Lung Cancer : abstr. P3.04-20, 23 Sep 2018.
Duma N, et al. Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy. 19th World Conference on Lung Cancer : abstr. P1.01-17, 23 Sep 2018.
Rights and permissions
About this article
Cite this article
News from 19th World Conference on Lung Cancer. Reactions Weekly 1724, 6–7 (2018). https://doi.org/10.1007/s40278-018-52985-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-52985-6